- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT03587038
OKN-007 i kombination med adjuverende temozolomid kemoradioterapi til nydiagnosticeret glioblastom
Feasibility Pilotundersøgelse af OKN-007 i kombination med adjuverende temozolomid kemoradioterapi hos patienter med nyligt diagnosticeret glioblastom
This is a pilot study exploring the potential benefit of adding OKN-007 with Temozolomide for treatment in patients with malignant Glioblastoma undergoing adjuvant concomitant radiotherapy. This drug combination is expected to have an anti-cancer effect in patients who have experienced disease progression after first line treatment.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Forenede Stater, 73117
- Stephenson Cancer Center, University of Oklahoma Health Sciences Center
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Patients have newly diagnosed histologically proven WHO grade III or grade IV Glioblastoma Multiforme (GBM).
- Patients at initial presentation of GBM must undergo an adequate surgical resection of the primary lesion; patients must be registered within 49 days (7 weeks) of the surgery.
- Patients must have available and be willing to submit a minimum of five unstained slides tumor tissue specimens from the GBM surgery or open biopsy for MGMT status analysis and molecular profile analysis.
- ECOG performance status within 0 - 2
- Full recovery (< grade 1) from the adverse events associated with prior surgery or any earlier intervention and a minimum of 28 days from the administration of any investigational agent
- Adequate renal, liver and bone marrow function: Leukocytes >3,000/mcL; Absolute neutrophil count >1,500/mcL; Platelets >100,000/mcL; AST / ALT (SGPT) <2.5 x ULN; Total bilirubin ≤ 1.5 x institutional upper limit of normal (IULN) (except Gilbert's Syndrome, who must have a total bilirubin < 3.0 mg/dL); Creatinine within normal limits
- Patients must be ≥ 18 years of age
- Patients must be willing to have blood draws for PK analysis
- All patients must have a CT or MRI of the brain within 14 days prior to registration. The brain CT or MRI should be performed with intravenous contrast (unless contraindicated).
- Patients must be informed of the investigational nature of this study and must sign and give written informed consent for this protocol in accordance with institutional and federal guidelines.
- Life expectancy ≥ 3 months, allowing adequate follow up of toxicity evaluation and progression-free survival evaluation;
- Female patient, if of childbearing potential, has a negative serum pregnancy test within 72 hours of taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 120 days after the last dose of study treatment
- Male patient agrees to use an adequate method of contraception
- Birth control should be used from the signing of the patient consent form and for 120 days following the last dose of study treatment.
- In addition, men must not donate sperm during study therapy and for 120 days after receiving the last dose of study treatment.
Exclusion Criteria:
- Second primary malignancy (except adequately treated basal cell carcinoma of the skin).
- Patients who had another malignancy in the past, but have been free of active disease for more than 2 years, are eligible
- Have received treatment within the last 28 days with a drug that has not received regulatory approval for any indication at the time of study entry
- Serious concomitant systemic disorders (for example, active infection or abnormal electrocardiogram (ECG) indicative of cardiac disease) that, in the opinion of the investigator, would compromise the safety of the patient and his/her ability to complete the study
- Patients with moderate or severe renal impairment (calculated creatinine clearance of < 60 mL/min)
- Patients with sodium, potassium, or creatinine serum electrolytes > grade 2.
- Screening ECG abnormality documented by the investigator as medically significant
- Inability to comply with protocol or study procedures.
- Women who are pregnant or breastfeeding.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: OKN-007 3 days per week plus temozolomide
OKN-007: 60 mg/kg, IV, 3 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
|
Eksperimentel: OKN-007 5 days per week and temozolomide
OKN-007: 60 mg/kg, IV, 5 times a week Temozolomide: 75 mg/m2, oral, once daily for 42 days Radiotherapy: 60 Gy administered in 30 fractions |
400 mg OKN-007/mL in a phosphate buffer 75 mg/m2 standard of care treatment to be given 1 to 2 hours after OKN-007 |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The maximum tolerated dose and the type of dose limiting toxicities
Tidsramme: 5 years
|
To determine how well patients are able to tolerate combination of OKN-007, temozolomide, and radiotherapy. Adverse events will be tabulated using MedDRA. The severity of the AE will be graded by the Investigator using the NCI CTCAE, version 4.03. |
5 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of participants who experience progression-free survival
Tidsramme: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who do not experience progression |
5 years
|
|
Number of participants who comply with study treatment plan
Tidsramme: 5 years
|
To evaluate the clinical compliance of participants receiving combination OKN-007 and TMZ |
5 years
|
|
Number of participants who are able to receive a reduction in steroid dose
Tidsramme: 5 years
|
To evaluate whether study drug combination allows for a reduced steroid dosage |
5 years
|
|
Number of participants who experience overall survival
Tidsramme: 5 years
|
To evaluate the proportion of patients who receive combination OKN-007 and TMZ who experience overall survival |
5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: James Battiste, MD, Principal Investigator
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Neoplasmer
- Neoplasmer efter histologisk type
- Neoplasmer, kirtel og epitel
- Astrocytom
- Gliom
- Neoplasmer, Neuroepithelial
- Neuroektodermale tumorer
- Neoplasmer, kimceller og embryonale
- Neoplasmer, nervevæv
- Glioblastom
- Organiske kemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Azoler
- Fysiske fænomener
- Dacarbazine
- Triazener
- Imidazoler
- Elektromagnetiske fænomener
- Magnetiske fænomener
- Elektromagnetisk stråling
- Stråling
- Elementære partikler
- Lys
- Optiske fænomener
- Stråling, ikke -ioniserende
- Temozolomid
- Fotoner
- OKN 007
Andre undersøgelses-id-numre
- OU-SCC-Oblato-001
- OKN-007 (Andet bevillings-/finansieringsnummer: Oblato Inc)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .